EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know

Program Overview

PAH Diagnostic Tools

PAH: Importance of Early Diagnosis to Improve Patient Outcomes

Diagnostic Algorithm for PH

Echocardiographic Probability of PH in Symptomatic Patients With a Suspicion of PH

Other Echocardiographic PH Signs

PAH Diagnostic Tools (cont)

Hemodynamic Definitions of PH as Assessed by RHC

Hemodynamic Parameters Measured or Derived From RHC

PAH Treatment: General Strategy

PAH Treatment: General Measures

PAH Treatment: Supportive Therapy

PAH Treatment: Specific Drug Therapy

Prognostic Evaluation and Risk Assessment

Initial Combination Therapy for High-Risk Patients With PAH

Initial Combination Therapy for Low/Intermediate-Risk Patients With PAH

Initial Use of Ambrisentan Plus Tadalafil in PAH: The AMBITION Trial

AMBITION Trial: Primary Endpoint* Results

ERS/ESC Evidence-Based Treatment Algorithm for Patients With PAH

PAH Therapies Target Diverse Vasomotor Pathways

Combination Therapy in PAH: Rationale and Potential Clinical Benefits

Role of Monotherapy for the Treatment of PAH

Pathobiology of PAH

Initial Combination Therapy for the Treatment of PAH

AMBITION: Efficacy Results

AMBITION Primary Endpoint* Results by Subgroup

Initial vs Sequential Combination Therapy: How to Choose?

Follow-Up Strategy for Patients With PAH

Conclusions

Conclusions (cont)

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)